Conversely, in prostate cancer, FOXA2 mutations are rare/absent, whereas FOXA1 mutations are common, with diverse experimental evidence that different classes of FOXA1 mutations in prostate cancer are dominant and gain of function. The gene discussed is FOXA1; the disease is prostate carcinoma.